Oral Semaglutide Cuts Heavy Drinking Days in Phase 2 AUD Trial
A 50-participant phase 2 trial missed its primary craving endpoint but reduced heavy drinking days, drinks per drinking day and cannabis use days — one of several late-July GLP-1 readouts pushing the class past metabolic endpoints.
30 July 20268 min read